US-based Ubimed has selected medical device firm Corpak MedSystems to distribute its Lifenest Sleep System in the hospital market in the UK and the Republic of Ireland.
Lifenest is a woven cradle offering diverse applications for the neonatal (NICU) setting, noted Corpak.
Ubimed president Dr Jose Bensoussan said: "The Lifenest Sleep System was specifically designed for babies’ safety, comfort and hygiene."
Ubimed has developed Lifenest to prevent pressure ulcers and positional Plagiocephaly, as well as to reduce the risk of rebreathing and hospital acquired infections (HAIs).
In addition, Lifenest will improve the efficiency of phototherapy treatment and newborn temperature control, as well as helps reduce babies’ stay in the NICU.
Corpak MedSystems CEO Frank McCaney said: "Corpak’s emphasis is on introducing innovative products, developed both internally and from partnerships that improve clinical outcomes while lowering overall costs."
Corpak president and COO Tom Kuhn added: "Corpak originally created the ‘Anti-IV’ or AIV product category targeted at reducing tubing misconnections in the NICU. Lifenest continues our legacy of providing pioneering safety products to this critical patient population."
Ubimed noted that Lifenest is a medical device, which is listed in FDA, as well as registered in Canada, Australia, Russia, Europe, Korea and Saudi Arabia.
